NASDAQ:EWTX Edgewise Therapeutics Q3 2024 Earnings Results & Report $36.28 -2.17 (-5.64%) Closing price 04:00 PM EasternExtended Trading$36.30 +0.02 (+0.04%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Edgewise Therapeutics beat analyst earnings expectations in its Q3 2024 results, released November 7, 2024. The company reported EPS of -$0.36 versus the -$0.37 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 7, 2024Conference Call7:00 AM ET Edgewise Therapeutics EPS ResultsActual EPS-$0.36Consensus EPS -$0.37Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEdgewise Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsEdgewise Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Edgewise Therapeutics Q3 2024 Earnings FAQ Did Edgewise Therapeutics beat earnings estimates for Q3 2024? Edgewise Therapeutics (NASDAQ:EWTX) reported earnings of -$0.36 per share for Q3 2024, beating the consensus estimate of -$0.37. The report was announced on Thursday, November 7, 2024. When is Edgewise Therapeutics' next earnings date? Edgewise Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Edgewise Therapeutics on the company's earnings history page. Edgewise Therapeutics Earnings HeadlinesEdgewise’s EQUINOX-HFpEF Trial: A Fresh Catalyst in the Heart Failure PipelineOctober 13 at 12:31 PM | tipranks.comEdgewise Therapeutics Doses First Patient in Trial of Investigational Heart Failure DrugOctober 8, 2026 | finance.yahoo.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 13 at 1:00 AM | Stansberry Research (Ad)Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock DownOctober 8, 2026 | rttnews.comEdgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400October 8, 2026 | prnewswire.comEdgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?October 2, 2026 | finance.yahoo.comSee More Edgewise Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Edgewise Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edgewise Therapeutics and other key companies, straight to your email. Email Address About Edgewise TherapeuticsEdgewise Therapeutics (NASDAQ:EWTX) is a biopharmaceutical company focused on developing small-molecule therapies for severe neuromuscular and cardiovascular diseases. The company’s research is centered on muscle biology, with the goal of developing treatments that address the underlying mechanisms of muscle damage and dysfunction. Edgewise’s lead investigational product is sevasemten, formerly known as EDG-5506, a selective fast skeletal muscle myosin inhibitor being developed for dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. The company is also developing EDG-7500, an investigational cardiac myosin modulator intended for the treatment of hypertrophic cardiomyopathy and other cardiovascular conditions. Founded in 2017 and headquartered in Boulder, Colorado, Edgewise conducts research and clinical development activities through collaborations and clinical trials in the United States and other regions. Kevin Koch serves as the company’s president and chief executive officer.View Edgewise Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
